Related Experiment Video

Updated: Mar 8, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Optimal Control Model of Tumor Treatment with Oncolytic Virus and MEK Inhibitor

Yongmei Su1, Chen Jia1, Ying Chen1

  • 1School of Mathematics and Physics, University of Science and Technology Beijing, Beijing, China.

Biomed Research International
|January 19, 2017
PubMed

Insights

This study introduces a mathematical model for oncolytic virus therapy combined with MEK inhibitors to treat tumors. It identifies optimal inhibitor dosages to maximize therapeutic benefits and minimize adverse effects.

Area of Science:

  • Oncology
  • Mathematical Biology
  • Virology

Background:

  • Tumors pose a significant threat to human health.
  • Oncolytic viruses offer a targeted approach to cancer treatment by selectively infecting and destroying cancer cells.
  • Mathematical modeling is crucial for understanding complex tumor-virus interactions and optimizing therapeutic strategies.

Purpose of the Study:

  • To develop a novel mathematical model for tumor therapy utilizing oncolytic viruses and MEK inhibitors.
  • To analyze the stability of the proposed tumor-virus-inhibitor model.
  • To determine optimal MEK inhibitor dosages for enhanced oncolytic virotherapy.

Main Methods:

  • Development of a new mathematical model integrating tumor cells, oncolytic viruses, and MEK inhibitor dynamics.
  • Stability analysis of the mathematical model.
  • Formulation and solution of an optimal control problem to determine ideal MEK inhibitor administration strategies.
  • Computational simulations to validate theoretical findings.

Main Results:

  • The study provides a theoretical framework for understanding the combined effects of oncolytic viruses and MEK inhibitors.
  • Stability analysis confirms predictable dynamics within the model.
  • Optimal control strategies were derived, balancing the dual role of MEK inhibitors in enhancing viral entry and limiting viral replication.
  • Simulations demonstrated the efficacy of the proposed optimal control strategies.

Conclusions:

  • The mathematical model offers valuable insights into optimizing oncolytic virus therapy with MEK inhibitors.
  • Optimal control strategies can effectively balance the beneficial and detrimental effects of MEK inhibitors.
  • This research paves the way for more effective and personalized cancer treatment regimens using combined therapies.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.6K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K